Qureight raises $20M in Series B to expand its AI-driven imaging research platform for cardiopulmonary clinical trials.
Key Details
- 1Qureight raised $20 million in Series B funding.
- 2The company is based in the UK and focuses on lung and heart disease clinical trials.
- 3Their platform offers AI-derived quantitative imaging biomarkers and CRO services.
- 4The technology is already used by biopharmas for trials involving fibrotic lung diseases.
- 5Funds will support an AI imaging lab built around 3D deep learning for chest imaging.
- 6Qureight plans expansion into diseases like asthma, pulmonary hypertension, and drug-induced lung toxicity.
Why It Matters
Qureight's enhanced platform and new imaging lab may accelerate development and deployment of AI biomarkers for a range of lung and heart diseases. This supports more efficient clinical trials and fosters broader application of imaging AI in drug development and disease monitoring.
Source
Radiology Business
Related News
•AuntMinnie
AI Triage Tool Speeds Up ICH Head CT Turnaround in ED
AI-based triage for intracranial hemorrhage on head CT reduced emergency department report turnaround by 13 minutes.
•Cardiovascular Business
FDA Clears Elucid's AI-Driven FFR-CT Solution for Cardiac Imaging
Elucid's FFR-IQ, an AI-powered noninvasive FFR-CT tool, receives FDA clearance for clinical use.
•Radiology Business
FDA Approves SimBioSys AI Tool for Breast Cancer Risk via MRI
SimBioSys received FDA clearance for TumorSight Risk, an AI tool assessing breast cancer recurrence risk using MRI.